A clear cell autonomous effect of PARP inhibitors has been demonstrated in non-CRC tumours [135, 136]; however, recent findings suggest that the efficacy of PARP inhibitors may depend on STING-driven CD8 + T cell recruitment in triple-negative breast cancer [137]. The gene discussed is PARP1; the disease is colorectal carcinoma.